Safety Evaluation of DREPADOM - Home Care Services and Hospitalizations for Sickle Cell Disease Patients
Launched by SOUTIEN AUX ACTIONS CONTRE LES MALADIES DU GLOBULE ROUGE · Dec 12, 2022
Trial Information
Current as of January 21, 2025
Completed
Keywords
ClinConnect Summary
This prospective, observational study will take place, as follows:
Calculation of the PRESEV score in the ER will determine or not eligibility of the patient in the DREPADOM structure. With a low score, a patient is eligible for home monitoring and after duly provided information, can sign a patient consent for the use of personal medical data.
The coordinating nurse from DREPADOM can then set up a whole network, with the delivery of oxygen supply at the patient's house, dispatch of a medical prescription to a neighboring pharmacy and daily visits from homecare service providers. Both opi...
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • SS or Sβ0
- • Adult patients with a low PRESEV score
- Exclusion Criteria:
- • SC/Sβ+ patients
- • SCD adult patients with an intermediate or high PRESEV score
- • Pregnant or breastfeeding women
- • Homeless patient
- • Patients without Social Security
- • Patient deprived of liberty by judicial or administrative decision or patient under guardianship
Trial Officials
Pablo BARTOLUCCI, PROFESSOR
Principal Investigator
Soutien aux Actions contre les Maladies du Globule Rouge
About Soutien Aux Actions Contre Les Maladies Du Globule Rouge
Soutien aux Actions Contre les Maladies du Globule Rouge (SAMG) is a dedicated clinical trial sponsor focused on advancing research and treatment options for red blood cell disorders. Committed to improving patient outcomes, SAMG collaborates with leading healthcare professionals, academic institutions, and industry partners to design and implement innovative studies that address the complexities of these diseases. By prioritizing rigorous scientific methodology and ethical standards, SAMG aims to enhance understanding, develop new therapies, and ultimately contribute to the well-being of individuals affected by red blood cell conditions.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Creteil, , France
People applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Discussion 0
Similar Trials